Literature DB >> 29357251

Salutaxel, a Conjugate of Docetaxel and a Muramyl Dipeptide (MDP) Analogue, Acts as Multifunctional Prodrug That Inhibits Tumor Growth and Metastasis.

Xiaoming Wen1, Purong Zheng1, Yao Ma2, Yingye Ou1, Weixin Huang1, Shuo Li1, Shoujia Liu1, Xuan Zhang1, Ziyu Wang1, Qianli Zhang1, Wenming Cheng1, Ruwen Lin1, Hongzu Li1, Youyou Cai1, Chunyun Hu1, Ningbin Wu1, Long Wan1, Tingting Pan1, Jinlong Rao1, Xuelu Bei1, Weibin Wu1, Jian Jin1, Jie Yan1, Gang Liu2.   

Abstract

Salutaxel (3) is a conjugate of docetaxel (7) and a muramyl dipeptide (MDP) analogue. Docetaxel (7) has been recognized as a highly active chemotherapeutic agent against various cancers. MDP and its analogues are powerful potentiators of the antitumor actions of various tumor-necrotizing agents. This article documents the discovery of compound 3 and presents pharmacological proof of its biological function in tumor-bearing mice. Drug candidate 3 was superior to compound 7 in its ability to prevent tumor growth and metastasis. Compound 3 suppressed myeloid-derived suppressor cell (MDSC) accumulation in the spleens of tumor-bearing mice and decreased various serum inflammatory cytokines levels. Furthermore, compound 3 antagonized the nucleotide-binding oligomerization domain-like receptor 1 (NOD1) signaling pathway both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29357251     DOI: 10.1021/acs.jmedchem.7b01407

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

Review 1.  Self-assembling prodrug nanotherapeutics for synergistic tumor targeted drug delivery.

Authors:  Zhiren Wang; Jiawei Chen; Nicholas Little; Jianqin Lu
Journal:  Acta Biomater       Date:  2020-05-23       Impact factor: 8.947

Review 2.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

Review 3.  Emerging Nanotherapeutic Approaches to Overcome Drug Resistance in Cancers with Update on Clinical Trials.

Authors:  Syed Nasir Abbas Bukhari
Journal:  Pharmaceutics       Date:  2022-04-15       Impact factor: 6.525

Review 4.  Muramyl dipeptide-based analogs as potential anticancer compounds: Strategies to improve selectivity, biocompatibility, and efficiency.

Authors:  Eliza Iwicka; Justyna Hajtuch; Krystyna Dzierzbicka; Iwona Inkielewicz-Stepniak
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

5.  NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway.

Authors:  Xiaomin Ma; Yumin Qiu; Yanlin Sun; Lihui Zhu; Yunxue Zhao; Tao Li; Yueke Lin; Dapeng Ma; Zhenzhi Qin; Caiyu Sun; Lihui Han
Journal:  Cell Death Dis       Date:  2020-03-06       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.